- Home
- LII vs BGNE Comparison
LII vs BGNE Comparison
Compare LII & BGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LII
- BGNE
- Stock Information
- Founded
- LII 1895
- BGNE 2010
- Country
- LII United States
- BGNE Cayman Islands
- Employees
- LII N/A
- BGNE N/A
- Industry
- LII Industrial Machinery/Components
- BGNE Biotechnology: Pharmaceutical Preparations
- Sector
- LII Industrials
- BGNE Health Care
- Exchange
- LII Nasdaq
- BGNE Nasdaq
- Market Cap
- LII 22.4B
- BGNE 19.4B
- IPO Year
- LII 1999
- BGNE 2016
- Fundamental
- Price
- LII $611.20
- BGNE $184.71
- Analyst Decision
- LII Buy
- BGNE Buy
- Analyst Count
- LII 13
- BGNE 8
- Target Price
- LII $583.50
- BGNE $253.69
- AVG Volume (30 Days)
- LII 639.0K
- BGNE 387.3K
- Earning Date
- LII 01-29-2025
- BGNE 02-24-2025
- Dividend Yield
- LII 0.76%
- BGNE N/A
- EPS Growth
- LII 38.78
- BGNE N/A
- EPS
- LII 21.04
- BGNE N/A
- Revenue
- LII $5,151,100,000.00
- BGNE $3,351,304,621.00
- Revenue This Year
- LII $5.80
- BGNE $969.39
- Revenue Next Year
- LII $7.04
- BGNE $24.79
- P/E Ratio
- LII $28.95
- BGNE N/A
- Revenue Growth
- LII 4.68
- BGNE 50.22
- 52 Week Low
- LII $412.09
- BGNE $126.97
- 52 Week High
- LII $682.50
- BGNE $248.16
- Technical
- Relative Strength Index (RSI)
- LII 40.16
- BGNE 46.17
- Support Level
- LII $603.55
- BGNE $179.73
- Resistance Level
- LII $620.34
- BGNE $184.98
- Average True Range (ATR)
- LII 17.48
- BGNE 4.56
- MACD
- LII -5.02
- BGNE 0.94
- Stochastic Oscillator
- LII 13.86
- BGNE 82.40
About LII Lennox International Inc.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
About BGNE BeiGene Ltd.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.